US 12,454,576 B2
Nanobody based imaging and targeting of ECM in disease and development
Richard O. Hynes, Winchester, MA (US); Noor Jailkhani, Cambridge, MA (US); Hidde L. Ploegh, Boston, MA (US); and Yushu J. Xie, Brookline, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US); Children's Medical Center Corporation, Boston, MA (US); and Whitehead Institute for Biomedical Research, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US); Children's Medical Center Corporation, Boston, MA (US); and Whitehead Institute for Biomedical Research, Cambridge, MA (US)
Filed on Feb. 28, 2023, as Appl. No. 18/175,786.
Application 18/175,786 is a division of application No. 16/258,457, filed on Jan. 25, 2019, granted, now 11,597,769.
Claims priority of provisional application 62/621,811, filed on Jan. 25, 2018.
Prior Publication US 2023/0348605 A1, Nov. 2, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 47/68 (2017.01); A61K 49/00 (2006.01); A61K 49/08 (2006.01); A61K 51/10 (2006.01); A61P 35/04 (2006.01); B82Y 5/00 (2011.01); C07K 14/78 (2006.01); C07K 16/18 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 16/2842 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 47/6809 (2017.08); A61K 47/6813 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 49/0058 (2013.01); A61K 49/085 (2013.01); A61K 51/1027 (2013.01); A61K 51/1045 (2013.01); A61K 51/1051 (2013.01); A61K 51/1057 (2013.01); A61K 51/1093 (2013.01); A61P 35/04 (2018.01); C07K 14/78 (2013.01); C07K 16/18 (2013.01); C12N 5/0636 (2013.01); A61K 2039/505 (2013.01); A61K 2239/13 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/57 (2023.05); B82Y 5/00 (2013.01); C07K 2317/22 (2013.01); C07K 2317/569 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)] 9 Claims
 
1. A chimeric antigen receptor (CAR) construct comprising an ectodomain comprising a nanobody which is specific for and binds directly to a diseased state extracellular matrix (ECM) epitope, wherein the diseased state ECM epitope is present in greater amounts in a diseased tissue than in a normal tissue, a transmembrane domain, and an endodomain, wherein the nanobody comprises a complementarity determining region (CDR) 1, CDR2 and CDR3 comprising a) SEQ ID NO: 19, SEQ ID NO: 36, and SEQ ID NO: 53, respectively; b) SEQ ID NO: 25, SEQ ID NO: 42, and SEQ ID NO: 59, respectively; c) SEQ ID NO: 26, SEQ ID NO: 43, and SEQ ID NO: 60, respectively; or d) SEQ ID NO: 28, SEQ ID NO: 45, and SEQ ID NO: 62, respectively.